Profile data is unavailable for this security.
About the company
Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that are ineffective or have no treatments available. Its cell penetrating peptide (CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets, has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin (FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in a Phase I clinical program.
- Revenue in USD (TTM)0.00
- Net income in USD-35.36m
- Incorporated2005
- Employees26.00
- LocationLarimar Therapeutics IncTHREE BALA PLAZA EAST. SUITE 506BALA CYNWYD 19004United StatesUSA
- Phone+1 (617) 622-4003
- Fax+1 (302) 655-5049
- Websitehttps://larimartx.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ALX Oncology Holdings Inc | 0.00 | -123.48m | 196.03m | 58.00 | -- | 0.746 | -- | -- | -3.03 | -3.03 | 0.00 | 6.45 | 0.00 | -- | -- | 0.00 | -35.97 | -- | -38.40 | -- | -- | -- | -- | -- | -- | -- | 0.0354 | -- | -- | -- | -47.95 | -- | -- | -- |
| Adaptimmune Therapeutics PLC - ADR | 27.15m | -165.46m | 196.71m | 534.00 | -- | 2.39 | -- | 7.25 | -1.03 | -1.03 | 0.1684 | 0.4977 | 0.068 | -- | 6.63 | 50,838.95 | -41.44 | -40.76 | -49.29 | -47.20 | -- | -- | -609.46 | -701.17 | -- | -- | 0.00 | -- | 341.50 | -6.42 | -4.66 | -- | 3.52 | -- |
| Foghorn Therapeutics Inc. | 19.23m | -108.88m | 197.31m | 161.00 | -- | 1,761.72 | -- | 10.26 | -2.62 | -2.62 | 0.4623 | 0.0027 | 0.0416 | -- | 0.1282 | 119,428.60 | -23.55 | -- | -26.53 | -- | -- | -- | -566.27 | -- | -- | -- | 0.00 | -- | 1,357.77 | -- | -7.46 | -- | -- | -- |
| Annexon Inc | 0.00 | -141.95m | 201.47m | 80.00 | -- | 0.8236 | -- | -- | -2.86 | -2.86 | 0.00 | 4.84 | 0.00 | -- | -- | 0.00 | -49.62 | -44.08 | -53.76 | -46.89 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.92 | -- | 63.01 | -- |
| ACRO Biomedical Co Ltd | 896.50k | -15.79m | 204.14m | -- | -- | 414.79 | -- | 227.71 | -0.2629 | -0.2629 | 0.0149 | 0.0082 | 1.41 | 1.80 | -- | -- | -2,479.75 | -- | -2,959.87 | -- | 25.26 | -- | -1,761.25 | -- | 2.15 | -14,096.83 | 0.1377 | -- | 74.07 | -- | -6,454.13 | -- | -- | -- |
| Larimar Therapeutics Inc | 0.00 | -35.36m | 205.53m | 26.00 | -- | 1.85 | -- | -- | -1.55 | -1.55 | 0.00 | 2.56 | 0.00 | -- | -- | 0.00 | -34.48 | -46.88 | -38.11 | -52.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.18 | -- | 12.70 | -- |
| Alpha Tau Medical Ltd | 0.00 | -33.76m | 206.02m | 94.00 | -- | 1.95 | -- | -- | -0.5007 | -0.5007 | 0.00 | 1.53 | 0.00 | -- | -- | 0.00 | -41.59 | -- | -43.95 | -- | -- | -- | -- | -- | -- | -20.01 | 0.00 | -- | -- | -- | -23.80 | -- | -- | -- |
| Zomedica Corp | 18.93m | -17.01m | 208.44m | 85.00 | -- | 0.7795 | -- | 11.01 | -0.0174 | -0.0174 | 0.0193 | 0.2729 | 0.0676 | 1.89 | 14.40 | 222,705.90 | -6.08 | -17.78 | -6.21 | -18.33 | 72.12 | -- | -89.88 | -384.78 | 15.46 | -- | 0.0065 | -- | 358.01 | -- | 7.44 | -- | 74.64 | -- |
| Fennec Pharmaceuticals Inc | 0.00 | -21.28m | 209.95m | 10.00 | -- | 74.82 | -- | -- | -0.8168 | -0.8168 | 0.00 | 0.1068 | 0.00 | -- | -- | 0.00 | -75.43 | -59.18 | -82.67 | -64.40 | -- | -- | -- | -38,331.77 | -- | -32.69 | 0.8992 | -- | -100.00 | -- | 4.21 | -- | -- | -- |
| Natures Sunshine Products Inc | 421.91m | -390.00k | 210.76m | 800.00 | -- | 1.48 | 18.21 | 0.4995 | -0.0177 | -0.0177 | 21.69 | 7.48 | 1.73 | 1.98 | 36.72 | 527,387.50 | 0.2251 | 5.27 | 0.3244 | 7.54 | 69.79 | 73.01 | 0.1304 | 3.00 | 1.24 | -- | 0.0079 | 35.64 | -4.99 | 4.29 | -101.35 | -- | 6.76 | -- |
| Ocugen Inc | 0.00 | -81.35m | 215.75m | 84.00 | -- | 2.51 | -- | -- | -0.3787 | -0.3787 | 0.00 | 0.3793 | 0.00 | -- | -- | 0.00 | -75.89 | -83.81 | -86.12 | -96.15 | -- | -- | -- | -446,793.90 | -- | -- | 0.0265 | -- | -- | -- | -39.38 | -- | 74.43 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Deerfield Management Co. LPas of 31 Dec 2022 | 16.94m | 39.15% |
| CHI Advisors LLCas of 31 Dec 2022 | 3.47m | 8.03% |
| Perceptive Advisors LLCas of 31 Dec 2022 | 2.86m | 6.61% |
| Woodline Partners LPas of 31 Dec 2022 | 1.94m | 4.49% |
| Opaleye Management, Inc.as of 31 Dec 2022 | 1.56m | 3.61% |
| Verition Fund Management LLCas of 31 Dec 2022 | 1.48m | 3.41% |
| Mangrove Partnersas of 31 Dec 2022 | 1.29m | 2.99% |
| Great Point Partners LLCas of 31 Dec 2022 | 1.27m | 2.94% |
| The Vanguard Group, Inc.as of 31 Dec 2022 | 1.07m | 2.48% |
| Janus Henderson Investors US LLCas of 31 Dec 2022 | 927.27k | 2.14% |
